Loading
Histone Deacetylase Inhibitors Research / Protein Degradation and Inhibitors / Cholinesterase and Neurodegenerative Diseases · Journal article
Main Group Chemistry · September 4, 2026
Raises a question worth testing. It does not answer one.
This is a computational structure-activity relationship study that identified coumarin derivative C5 as a predicted HDAC2 inhibitor with favourable binding affinity, BBB permeability, and simulated inhibitory potency superior to SAHA. All findings are in silico; no experimental biochemical or cellular validation is reported, making this a hypothesis-generating precursor to drug development rather than evidence of efficacy.
Computational structure-based drug discovery with molecular docking, SAR analysis, and molecular dynamics simulation. Coumarin derivatives from PubChem database; in silico filtering and screening; no human, animal, or cell-based subjects.. Intervention: Compound C5 (novel coumarin-based HDAC2 inhibitor candidate) identified through computational design and optimisation.. Compared with: Vorinostat (SAHA), the clinical HDAC inhibitor standard; used as reference for predicted binding affinity and functional similarity..
2555 PubChem coumarin derivatives filtered to 1879 drug-like molecules; 46 novel derivatives designed based on 17 initial leads Compound C5 showed predicted HDAC2 IC₅₀ of 0.560 µM versus SAHA 1.116 µM C5 demonstrated binding affinities of −7.0 to −9.3 kcal/mol, exceeding SAHA at −7.3 kcal/mol
No toxicity or off-target binding predictions reported; BBB permeability assessed computationally only
This computational work identifies a candidate molecule for further experimental development but provides no evidence of clinical utility. Researchers may use C5 as a starting point for biochemical screening and cell-based validation; however, the gap between docking predictions and actual biological activity remains unbridge and must be experimentally determined before any clinical consideration.
Structure-based computational discovery of a novel HDAC2 inhibitor with predicted superior binding and activity; lacks experimental validation in cells or organisms, representing early-stage hypothesis-generating work.
As stated by the source record.
Quoted from the source exactly as published.
This computational work identifies a candidate molecule for further experimental development but provides no evidence of clinical utility. Researchers may use C5 as a starting point for biochemical screening and cell-based validation; however, the gap between docking predictions and actual biological activity remains unbridge and must be experimentally determined before any clinical consideration.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Histone deacetylase 2 (HDAC2) is a promising epigenetic target for cancer therapy; however, the clinical utility of Vorinostat (SAHA) is limited by poor selectivity, toxicity, and inadequate blood–brain barrier (BBB) permeability. A structure–activity relationship (SAR)-guided strategy was employed to identify novel coumarin-based HDAC2 inhibitors. A total of 2555 PubChem coumarin derivatives were filtered using Lipinski's criteria, yielding 1879 drug-like molecules for docking against HDAC2 (PDB ID: 7ZZT). Seventeen lead compounds guided the design of 46 novel derivatives. Docking identified compounds with binding affinities of −7.0 to −9.3 kcal/mol, exceeding SAHA (−7.3 kcal/mol). SAR analysis highlighted the coumarin scaffold, an additional aromatic ring, a 3–6 atom linker, a furan bridge, and terminal hydroxyl or methoxy groups as key structural features. Compound C5 exhibited high functional similarity with SAHA (R 2 = 0.898), favorable BBB permeability, superior predicted HDAC2 inhibition (IC 50 = 0.560 µM vs. 1.116 µM), enhanced predicted antiproliferative activity against MCF7, MDA-MB-231, HL-60, and U87MG cell lines, and stable binding confirmed by steered and 100 ns molecular dynamics simulations, identifying Asp104 as a key stabilizing residue.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.